Olympus CRP-Latex Assay Receives Clearance as Independent Cardiac Risk Marker
Orlando, FL, July 26, 2005 - Olympus has earned FDA clearance for its C-Reactive Protein (CRP) Latex assay as an independent cardiac risk marker. High Sensitive (Cardiac) application measurements, when used in conjunction with traditional clinical laboratory evaluations, may be useful as an independent marker of prognosis for recurrent events in patients with either stable coronary disease or acute coronary syndromes.
C-Reactive Protein is one of the most sensitive acute-phase reactants. Measurement of CRP can have a role in the detection and evaluation of infection, tissue injury, inflammatory disorders and associated diseases. The Olympus CRP Latex assay offers three applications covering a variety of measuring ranges to quantify C-Reactive Protein in human serum. Ranges include: Normal (5 - 170 mg/L), Sensitive (Cardiac) (0.5 -20 mg/L) and Highly Sensitive (Neonatal) (0.05 - 2.00 mg/L).
The Olympus CRP Latex assay is designed for use on the full line of Olympus chemistry-immuno analyzers, including the AU400/400e®, AU600®, AU640/640e®, AU2700® and AU5400®.
For additional information about the Olympus high sensitivity CRP Latex assay, contact Carole Dauscher, Product Manager, Olympus Diagnostic Systems Group, at 1-800-223-0125 x5654 or email: email@example.com.
About Olympus Diagnostic Systems Group
Olympus Diagnostic Systems Group provides innovative solutions that meet the high productivity demands of hospitals, integrated healthcare delivery networks, reference labs, blood banks and pharmaceutical labs. Olympus offers the broadest standardized line of random access chemistry-immuno analyzers, along with lab automation systems, comprehensive patient safety systems, blood bank analyzers and reagents. Olympus solutions save laboratories time, enhance patient safety, maximize productivity, and deliver fast, reliable results.
Olympus is a precision technology leader, designing and delivering innovative solutions in healthcare and consumer electronics worldwide.
Olympus works collaboratively with its customers and its parent company, Tokyo-based Olympus Corporation, to leverage R&D investment in precision technology and manufacturing processes across diverse business lines. These include:
- Gastrointestinal endoscopes, accessories, and minimally invasive surgical products;
- Advanced clinical and research microscopes;
- Lab automation systems, chemistry-immuno and blood bank analyzers and reagents; and
- Digital and film cameras, and digital voice recorders.
In the U. S. and Canada, Olympus serves healthcare, scientific and commercial laboratory markets with integrated product solutions and financial, educational and consulting services that help customers efficiently, reliably, safely, and easily achieve superior results. Olympus is the leader in gastrointestinal endoscopy and clinical and educational microscopes. The company's market-leading consumer electronics business spans North and South America. For more information, visit www.olympusamerica.com.